We demonstrated that RCE plus Oxa activates tumor-infiltrating human PD-1+CD8+ T cells, thereby effectively killing human PD-L1-expressing mouse MC38 CRC cells. The gene discussed is CD8A; the disease is colorectal carcinoma.